Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2019

Authors

  • Jan M Bell University of Adelaide, Adelaide, South Australia, Australia
  • Alicia Fajardo Lubian Westmead Institute for Medical Research, Westmead, New South Wales, Australia;The University of Sydney, New South Wales, Australia;Westmead Hospital, Westmead, New South Wales, Australia
  • Sally Partridge Westmead Institute for Medical Research, Westmead, New South Wales, Australia;The University of Sydney, New South Wales, Australia;Westmead Hospital, Westmead, New South Wales, Australia
  • Thomas Gottlieb The University of Sydney, New South Wales, Australia;Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia
  • Jonathan Iredell Westmead Institute for Medical Research, Westmead, New South Wales, Australia;The University of Sydney, New South Wales, Australia;Westmead Hospital, Westmead, New South Wales, Australia
  • Denise A Daley Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
  • Geoffrey W Coombs Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia ;Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

DOI:

https://doi.org/10.33321/cdi.2020.44.80

Keywords:

Australian Group on Antimicrobial Resistance (AGAR), antibiotic resistance, bacteraemia, gram-negative, Escherichia coli, Enterobacter, Klebsiella

Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2019 survey was the seventh year to focus on bloodstream infections, and included Enterobacterales, Pseudomonas aeruginosa and Acinetobacter species.

Eight thousand eight hundred and fifty-seven isolates, comprising Enterobacterales (7,983; 90.1%), P. aeruginosa (764; 8.6%) and Acinetobacter species (110; 1.2%), were tested using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2020). Of the key resistances, resistance to the third-generation cephalosporin ceftriaxone was found in 13.3%/13.3% (CLSI/EUCAST criteria) of Escherichia coli and 8.4%/8.4% of Klebsiella pneumoniae. Resistance rates to ciprofloxacin were 16.0%/16.0% for E. coli, 10.2%/10.2% for K. pneumoniae complex, 5.9%/5.9% for Enterobacter cloacae complex, and 4.1%/9.3% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 3.2%/5.7%, 4.7%/8.5%, 14.8%/21.4%, and 6.9%/12.5% for the same four species/complex respectively. Twenty-nine isolates from 29 patients were shown to harbour a carbapenemase gene: 15 blaIMP-4, five blaOXA-181, four blaOXA-23 (one with blaOXA-58 also), three blaNDM-4/5, one blaGES-5, and one blaIMP-1.

Downloads

Download data is not yet available.

References

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA; 2020.

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints – breakpoints and guidance. Version 10.0, 25 January 2020. Available at: http://www.eucast.org/clinical_breakpoints/.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

Ellem J, Partridge SR, Iredell JR. Efficient direct extended-spectrum β-lactamase detection by multiplex real-time PCR: accurate assignment of phenotype by use of a limited set of genetic markers. J Clin Microbiol. 2011;49(8):3074–7.

Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. Available from: https://github.com/tseemann/nullarbor.

Seemann T. Abricate. San Francisco; Github. Available from: https://github.com/tseemann/abricate.

National Center for Biotechnology Information (NCBI). AMRFinderPlus. [Website.] Bethesda; United States National Library of Medicine, NCBI: 2020. Available from: https://ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/.

Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom. 2017;3(10):e000131.

Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020;48(D1):D517–25.

Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J, for the Australian Group for Antimicrobial Resistance. Gram-negative Survey 2011 Antimicrobial Susceptibility Report. Adelaide; 2011. Available from: http://www.agargroup.org/files/AGAR20GNB0820Report20FINAL.pdf.

Sheng WH, Badal RE, Hsueh PR, SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–8.

European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. Solna: ECDC; 18 Nov 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018.

Downloads

Published

15/10/20

How to Cite

Bell, Jan M, Alicia Fajardo Lubian, Sally Partridge, Thomas Gottlieb, Jonathan Iredell, Denise A Daley, and Geoffrey W Coombs. 2020. “Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-Negative Sepsis Outcome Programme (GNSOP) Annual Report 2019”. Communicable Diseases Intelligence 44 (October). https://doi.org/10.33321/cdi.2020.44.80.

Issue

Vol. 44 (2020)

Section

Annual report

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 > >>